Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.56 |
| ▸ | RAF1 | P04049 | 4/20 | 0.53 |
| ▸ | MAP2K1 | Q02750 | 4/20 | 0.53 |
| ▸ | STK4 | Q13043 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 8/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | GAK | O14976 | 2/20 | 0.48 |
| ▸ | SRC | P12931 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PLK1 | P53350 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4900810 | 0.82 | MAP2K1 (0.64) | RAF1MAP2K1SRC | |
| SCHEMBL4900624 | 0.81 | SRC (0.64) | EGFRERBB2GAKSRC | |
| SCHEMBL6380922 | 0.80 | PDE4B (0.71) | PDE4BRAF1MAP2K1STK4EGFR | |
| SCHEMBL6386795 | 0.76 | PDE4B (0.58) | PDE4BRAF1MAP2K1STK4EGFR | |
| SCHEMBL3873352 | 0.76 | PDE4B (0.55) | PDE4BRAF1MAP2K1STK4EGFR | |
| SCHEMBL1893705 | 0.75 | PDE4B (0.71) | PDE4BRAF1MAP2K1STK4EGFR | |
| SCHEMBL4894140 | 0.74 | SRC (0.71) | RAF1MAP2K1EGFRSRC | |
| SCHEMBL6382347 | 0.74 | EGFR (0.70) | PDE4BRAF1MAP2K1STK4EGFR | |
| Hydrochloric Acid SCHEMBL6381171 | 0.73 | EGFR (0.70) | PDE4BRAF1MAP2K1STK4EGFR | |
| SCHEMBL6384191 | 0.72 | PDE4B (0.58) | PDE4BRAF1MAP2K1STK4EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070913-A1 | Thieno [ 3,2-b] pyridine-6-carbonitriles and thieno [2,3-b] pyridine-5-carbonitriles as protein kinase inhibitors | BOSCHELLI DIANE H | 2008-03-20 | — | — | US | disclosed |
| US-7276519-B2 | Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors | WYETH (US) | 2007-10-02 | — | — | US | disclosed |
| US-6987116-B2 | Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors | WYETH (US) | 2006-01-17 | — | — | US | disclosed |
| EP-1565474-A2 | THIENO[3,2-B]PYRIDINE-6-CARBONITRILES AND THIENO[2,3-B]PYRIDINE-5-CARBONITRILES AS PROTEIN KINASE INHIBITORS | Wyeth (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004048386-A9 | THIENO[3,2-b]PYRIDINE-6-CARBONITRILES AND THIENO[2,3-b]PYRIDINE-5-CARBONITRILES AS PROTEIN KINASE INHIBITORS | WYETH CORP (US) | 2005-07-14 | — | — | WO | disclosed |
| US-20040242883-A1 | Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors | WYETH | 2004-12-02 | — | — | US | disclosed |
| US-20040138251-A1 | Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors | WYETH | 2004-07-15 | — | — | US | disclosed |
| WO-2004048386-A2 | THIENO[3,2-b]PYRIDINE-6-CARBONITRILES AND THIENO[2,3-b]PYRIDINE-5-CARBONITRILES AS PROTEIN KINASE INHIBITORS | WYETH (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070913-A1 | Thieno [ 3,2-b] pyridine-6-carbonitriles and thieno [2,3-b] pyridine-5-carbonitriles as protein kinase inhibitors | PKN2, TNNI3K, PKN1 | PDE4B 1683/4885RAF1 27/4885MAP2K1 327/4885 |
| US-20040242883-A1 | Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors | PKN2, PTK2B, PKN1 | PDE4B 2121/4885RAF1 15/4885MAP2K1 265/4885 |
| US-20040138251-A1 | Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors | PTK2B, PKD1, PKN1 | PDE4B 2250/4885RAF1 10/4885MAP2K1 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.